In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

被引：2
|
作者：
Meylan, M.
Sun, C-M.
Elaidi, R-T.
Moreira, M.
Bougouin, A.
Verkarre, V.
Bennamoun, M.
Chevreau, C. M.
Borchiellini, D.
Barthelemy, P.
Pannier, D.
Maillet, D.
Goupil, M. Gross
Tournigand, C.
Braychenko, E.
Phan, L.
Oudard, S.
Fridman, W-H.
Sautes-Fridman, C.
Vano, Y-A.
机构：
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1451MO
引用
收藏
页码：S1207 / S1207
页数：1
相关论文
共 50 条
  • [41] Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study.
    Meza, Luis A.
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Dorff, Tanya B.
    Lyou, Yung
    Frankel, Paul Henry
    Llamas, Marian
    Hsu, Joann
    Zengin, Zeynep Busra
    Salgia, Nicholas
    Malhotra, Jasnoor
    Chawla, Neal Shiv
    Gillece, John D.
    Reining, Lauren J.
    Trent, Jeffrey M.
    Takahashi, Motomichi
    Oka, Kentaro
    Higashi, Seiya
    Highlander, Sarah K.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Adjuvant nivolumab plus ipilimumab (NIVO plus IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
    Motzer, R. J.
    Russo, P.
    Gruenwald, V.
    Tomita, Y.
    Zurawski, B.
    Parikh, O. A.
    Buti, S.
    Barthelemy, P.
    Goh, J. C. H.
    Ye, D.
    Lingua, A.
    Lattouf, J-B.
    Escudier, B.
    George, S.
    Shuch, B.
    Simsek, B.
    Spiridigliozzi, J.
    Chudnovsky, A.
    Bex, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1430 - S1430
  • [43] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [44] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
    Motzer, Robert
    Rini, Brian, I
    McDermott, David F.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael A.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Neiman, Victoria
    Bracarda, Sergio
    Tykodi, Scott S.
    Barthelemy, Philippe
    Leibowitz-Amit, Raya
    Plimack, Elizabeth R.
    Oosting, Sjoukje F.
    Redman, Bruce
    Melichar, Bohusiav
    Powles, Thomas
    Nathan, Paul
    Oudard, Stephan
    Pook, David
    Choueiri, Toni K.
    Donskov, Frede
    Grimm, Marc-Oliver
    Gurney, Howard
    Heng, Daniel Y. C.
    Kollmannsberger, Christian K.
    Harrison, Michael R.
    Tamita, Yoshihiko
    Duran, Ignacio
    Gruenwold, Viktor
    McHenry, M. Brent
    Mekan, Sabeen
    Tannir, Nizar M.
    LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
  • [45] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    McHenry, M. Brent
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [46] Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
    Atkins, Michael B.
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian, I
    Jiang, Ruiyun
    Federov, Viktor
    Lee, Chung-Wei
    Desilva, Heshani
    Tannir, Nizar M.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S17 - S18
  • [47] Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)
    Swami, U.
    Jo, Y. Jung
    Thomas, V. Mathew
    Gebrael, G.
    Li, H.
    Sayegh, N.
    Tripathi, N.
    Srivastava, A.
    Nordblad, B.
    Dal, E.
    Brundage, J.
    Campbell, P.
    Fortuna, G. Galarza
    Chehade, C. Hage
    Maughan, B. L.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1021 - S1021
  • [48] Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab plus nivolumab (ipi plus nivo) vs. PD-1/L1 inhibitor (PDI) plus tyrosine kinase inhibitor (TKI)
    Gebrael, G.
    Jo, Y. Jung
    Thomas, V. Mathew
    Li, H.
    Fortuna, G. Galarza
    Sahu, K.
    Sayegh, N.
    Tripathi, N.
    Chigarira, B.
    Srivastava, A.
    Chehade, C. Hage
    Nordblad, B.
    Dal, E.
    Brundage, J.
    Maughan, B. L.
    Agarwal, N.
    Swami, U.
    ANNALS OF ONCOLOGY, 2023, 34 : S1022 - S1022
  • [49] Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC)
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    Stadler, Walter M.
    Chasalow, Scott
    Ross-Macdonald, Petra
    Jure-Kunkel, Maria
    Sznol, Mario
    Simon, Jason S.
    CANCER RESEARCH, 2015, 75
  • [50] Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
    Tannir, N. M.
    Albiges, L.
    Mcdermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Barthelemy, P.
    Plimack, E. R.
    Portat, C.
    George, S.
    Donskov, F.
    Atkins, M. B.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M. -o.
    Barrios, C.
    Tomita, Y.
    Castellano, D.
    Gruenwald, V.
    Rini, B. I.
    Jiang, R.
    Desilva, H.
    Fedorov, V.
    Lee, C. -w.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1026 - 1038
12345